Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
More people are being affected by Alpha-1 Antitrypsin Deficiency (AATD) lately since doctors now are aware of the latest methods to diagnose and treat it. Diagnostic accuracy has gone up since more training has been made available to the public and people who work in healthcare. This makes it more important to get things fixed.
Because research and development are still going on, solutions for AATD are getting better. To try to make things better for patients, work is being done on gene therapies and personalized methods right now.
Pharmaceutical and science firms are investing a lot of cash in cutting-edge technologies to learn how to treat AATD and make the business world more competitive.
There are more times now than ever before when political groups, academic schools, and drug companies work together. Making relationships like these is one of the best ways to get people to work together. These agreements combine resources, make it easier for experts to share what they know, and speed up the process of making new AATD treatments and getting them out to people.
There are more and more specialized medicines for people with AATD as the market for them grows. Making drugs fit the specifics of each patient, like their genes, can help them get better results, have fewer side effects, and help the market grow.
It's getting more and more important for people with AATD to get care. Help programs for patients, payment laws, and government laws all work together to make sure that people with AATD can get the newest and best treatments.
Because technology is getting better and more exact signs are coming out, AATD is being treated better. These findings have changed the direction of the sector because they make it possible to find illnesses earlier, keep an eye on them over time, and treat them better.
More and more people around the world are not having enough alpha-1 antitrypsin. The market is going up because of this. People need good answers more than ever as they learn more and get better at figuring out what's wrong. This means there is a good chance for medicine companies to make money.
Pharmacies that do well sell themselves in a smart way to get a bigger share of the market. More tailored marketing, learning more, and working with medical experts are some of the things that are done to improve the care of AATD.
There are still problems with how easy and cheap it is to get care, even though some good things have happened. These issues need to be fixed so that more people can easily get AATD care and can do so without having to worry about money.
Alpha 1 Antitrypsin Deficiency Treatment Market Highlights:
Alpha-1 Antitrypsin Deficiency Treatment Market Overview
Alpha-1 Antitrypsin Deficiency Treatment Market Size was valued at USD 3.12 Billion in 2023. The Global Alpha-1 Antitrypsin Deficiency Treatment industry is projected to grow from USD 3.52 Billion in 2024 to USD 9.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.23% during the forecast period (2024 - 2032).
Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency. Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the market growth of the alpha-1 antitrypsin deficiency treatment.
Strategic mergers & acquisitions are also projected to boost alpha-1 antitrypsin deficiency treatment market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.
High unmet medical needs in developing economies are directly providing lucrative opportunities for the alpha-1 antitrypsin deficiency treatment market growth.
Market Influencers
The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.
Market Drivers
- Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive market growth of the alpha-1 antitrypsin deficiency treatment.
- Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs
- Rising awareness regarding alpha-1 antitrypsin deficiency
- High unmet medical needs in developing economies
- Increasing R&D expenditure by key players to develop innovative treatment options for AATD
Market Restraints
- Stringent government regulatory policies
- High cost of drugs
Alpha-1 Antitrypsin Deficiency Treatment Market Segmentation Insights
Alpha-1 Antitrypsin Deficiency Treatment Drugs Insights
- Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the alpha-1 antitrypsin deficiency treatment market growth.
- Bronchodilators: Used for prevention from upper respiratory tract infections.
- Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.
- Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.
Alpha-1 Antitrypsin Deficiency Treatment Route of Administration Insights
- Oral: This route of administration is expected to hold the largest alpha-1 antitrypsin deficiency treatment market share due to its high usage.
- Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.
- Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.
- Others: Consists of subcutaneous and intramuscular routes of administration.
Alpha-1 Antitrypsin Deficiency Treatment Distribution Channel Insights
- Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.
- Retail Pharmacy: They provide prescriptions that are intended to be used at home.
- Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.
Alpha-1 Antitrypsin Deficiency Treatment Regional Insights
- Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the market growth of alpha-1 antitrypsin deficiency treatment. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the market growth of the alpha-1 antitrypsin deficiency treatment in the region.
- Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the alpha-1 antitrypsin deficiency treatment market growth.
- Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world’s largest population and fast-developing healthcare industry which is anticipated to drive the market growth.
- Middle East & Africa: The market growth of alpha-1 antitrypsin deficiency treatment is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.
Key Players
- Kamada Pharmaceuticals (Israel)
- CSL Behring LLC (US)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- AstraZeneca (UK)
- Vectura Group plc (UK)
- Pfizer Inc. (US)
- Mylan Inc. (US)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
